Translate
Monte Rosa Therapeutics Inc
About
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 20 2026
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Mar 17 2026
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Mar 16 2026
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Feb 24 2026
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Jan 9 2026
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Recent Videos
24_02_26 Noticias de acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI
Feb 24, 2026
Monte Rosa: My Take on Their Sales Agreement Pause
Jan 11, 2026
GLUE Alert: Massive Price Targets Unlocked! + Key Lvl(30.86/24.11/19.10/15.40)🚀 #Shorts #trading
Jan 08, 2026
GLUE Monte Rosa Therapeutics Stock: 3 Scenarios + Thursday Predicted Opening Price? 🚨
Jan 07, 2026
Financials
Revenue
$123.67 M
Market Cap
$1.37 B
EPS
-0.46